P08.17 Mitotic checkpoint inhibition augments Tumor-Treating-Field (TTField) effects on glioblastoma cells

nork Kessler, A. F.
Argitaratua izan da Neuro Oncol (2017)

P09.21 Complete radiological response after subtotal resection in two Gglioblastoma patients treated with Tumor Treating Fields

nork Kessler, A. F., Linsenmann, T.
Argitaratua izan da Neuro Oncol (2017)

P14.59 Post-Market Surveillance Data of the EMEA region indicate good tolerability of TTFields in WHO Grade III Glioma

nork Keßler, A F, Ritz, R
Argitaratua izan da Neuro Oncol (2019)

P06.06 Is activating transcription factor 5 (ATF5) a new therapeutic target in astrocytomas of different WHO grades and varying biological behavior? An expression analysis

nork Feldheim, J. A., Keßler, A. F.
Argitaratua izan da Neuro Oncol (2016)

P08.20 Augmentation of Tumor-Treating-Field (TTField) effects on glioblastoma cells by mitotic checkpoint inhibition

nork Frömbling, G. E., Kessler, A. F.
Argitaratua izan da Neuro Oncol (2016)

P14.60 FET PET response upon radiochemotherapy followed by Tumor Treating Fields (TTFields) in a patient with progressive high-grade glioma

nork Keßler, A F, Weiland, J, Linsenmann, T, Ernestus, R, Hagemann, C, Löhr, M
Argitaratua izan da Neuro Oncol (2019)

P14.28 First report on the combination of axitinib and Tumor Treating Fields (TTFields) in three patients with recurrent glioblastoma

nork Keßler, A F, Weiland, J, Linsenmann, T, Ernestus, R, Hagemann, C, Löhr, M
Argitaratua izan da Neuro Oncol (2019)

O4.06 ANALYSIS OF RAF PROTEINS IN MALIGNANT GLIOMAS

nork Hagemann, C., Gloger, J., Kessler, A.F., Linsenmann, T., Vince, G.H., Ernestus, R., Löhr, M.
Argitaratua 2014

P04.33 Effects of Tumor Treating Fields (TTFields) on blood brain barrier (BBB) permeability

nork Kessler, A F, Schaeffer, C, Burek, M, Ruschig, U, Ernestus, R, Löhr, M, Förster, C, Hagemann, C
Argitaratua izan da Neuro Oncol (2018)

P01.13 EXPRESSION OF HUMAN ENDOGENOUS RETROVIRUS K (HERV-K) IN HUMAN ASTROCYTIC TUMORS

nork Kessler, A.F., Wiesner, M., Denner, J., Kämmerer, U., Löhr, M., Linsenmann, T., Vince, G.H., Ernestus, R., Hagemann, C.
Argitaratua 2014

OS4.3 The BReMen trial: Patients with benign meningioma - is rehabilitation really necessary?

nork Kessler, A F, Krause, K, Al-Shameri, B, Weiland, J, Linsenmann, T, Ernestus, R, Hagemann, C, Löhr, M, Jentschke, E
Argitaratua izan da Neuro Oncol (2018)

P11.28 Alteration of blood brain barrier (BBB) permeability by Tumor Treating Fields (TTFields) in vivo

nork Keßler, A F, Salvador, E, Domröse, D, Burek, M, Tempel Brami, C, Voloshin Sela, T, Giladi, M, Ernestus, R, Löhr, M, Förster, C, Hagemann, C
Argitaratua izan da Neuro Oncol (2019)

P01.050 Circulating MACC1 transcript plasma levels in glioblastoma patients segregate together with prognostic markers and treatment response

nork Hagemann, C, Neuhaus, N, Dahlmann, M, Kessler, A F, Kobelt, D, Herrmann, P, Eyrich, M, Freitag, B, Freitag, B, Linsenmann, T, Monoranu, C M, Ernestus, R, Löhr, M, Stein, U
Argitaratua izan da Neuro Oncol (2018)